This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Want Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Hologic Stock Falls Despite Q3 Earnings and Revenue Beat, Margins Down
by Zacks Equity Research
HOLX posts better-than-expected Q3 results, but margin contraction and regional headwinds pressure investor sentiment.
Compared to Estimates, Hologic (HOLX) Q3 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for Hologic (HOLX) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Hologic (HOLX) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Hologic (HOLX) delivered earnings and revenue surprises of +2.86% and +1.68%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Hologic Focuses on Breast Health Turnaround This Year: Can It Deliver?
by Moumi Mondal
HOLX eyes a Breast Health rebound in Q4, backed by leadership changes, new strategy and Endomag momentum.
Seeking Clues to Hologic (HOLX) Q3 Earnings? A Peek Into Wall Street Projections for Key Metrics
by Zacks Equity Research
Get a deeper insight into the potential performance of Hologic (HOLX) for the quarter ended June 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
HOLX vs. EXAS: Which Cancer Diagnostics Stock Should You Retain Now?
by Moumi Mondal
EXAS gains edge over HOLX as rising Cologuard adoption, new launches and bullish EPS trends boost investor appeal.
Hologic's International Momentum Takes Shape: Will Execution Pay Off?
by Moumi Mondal
HOLX is leaning into international growth with Surgical division strength and untapped demand driving momentum abroad.
Hologic (HOLX) Laps the Stock Market: Here's Why
by Zacks Equity Research
In the closing of the recent trading day, Hologic (HOLX) stood at $65.37, denoting a +2.64% move from the preceding trading day.
Is Hologic Stock a Risky Investment Ahead of Its Q3 Earnings Report?
by Moumi Mondal
HOLX heads into Q3 earnings with revenue and EPS estimates down, tariff pressures mounting, and stock lagging peers.
Hologic Rides on AI-Powered Breast Health Innovations: What's Next?
by Moumi Mondal
HOLX advances breast health with AI tools like Genius Detection PRO and the upcoming Envision 3D platform.
Why Hologic (HOLX) Dipped More Than Broader Market Today
by Zacks Equity Research
The latest trading day saw Hologic (HOLX) settling at $63.26, representing a -2.1% change from its previous close.
Hologic, Inc. (HOLX) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Hologic (HOLX). This makes it worthwhile to examine what the stock has in store.
Hologic's GYN Surgical Dominance: What's Powering the Road Ahead?
by Moumi Mondal
HOLX's GYN Surgical arm gains momentum with Fluent Pro, global expansion and strategic acquisitions fueling growth.
Hologic (HOLX) Surpasses Market Returns: Some Facts Worth Knowing
by Zacks Equity Research
In the latest trading session, Hologic (HOLX) closed at $65.85, marking a +1.46% move from the previous day.
Is Hologic Stock's Low Valuation an Opportunity or a Value Trap?
by Moumi Mondal
HOLX trades below peers on P/S, but falling EPS, weak Breast Health sales and China risks cloud the outlook.
Hologic, Inc. (HOLX) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Hologic (HOLX). This makes it worthwhile to examine what the stock has in store.
Hologic Faces Molecular Drag, But Here's Why It's Not a Major Concern
by Moumi Mondal
HOLX's Molecular Diagnostics growth stays resilient, as new assays and test adoption offset funding headwinds.
Hologic (HOLX) Surpasses Market Returns: Some Facts Worth Knowing
by Zacks Equity Research
In the most recent trading session, Hologic (HOLX) closed at $65.11, indicating a +1.31% shift from the previous trading day.
How Hologic Leverages Its Financial Firepower to Drive Long-Term Value
by Moumi Mondal
Backed by robust profitability, HOLX deploys billions into acquisitions and repurchases to boost future earnings.
HOLX vs. COO: Which GYN Surgical Stock Is the Better Investment Now?
by Moumi Mondal
As demand for GYN surgical tools climbs, HOLX and COO battle it out. Find out which stock shows stronger growth momentum now.
Hologic, Inc. (HOLX) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Hologic (HOLX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Hologic (HOLX) Suffers a Larger Drop Than the General Market: Key Insights
by Zacks Equity Research
Hologic (HOLX) concluded the recent trading session at $64.14, signifying a -1.6% move from its prior day's close.
Hologic's Margin Stability Amid Tariffs: What's Behind the Confidence?
by Moumi Mondal
HOLX lifts margins despite tariffs and weak China sales, leaning on diagnostics strength and high-margin buys.
Can Hologic Lean on Its Strengths in a Tough Macroeconomic Climate?
by Moumi Mondal
HOLX grapples with global headwinds, but growth in Diagnostics and Breast Health service lifts confidence.